Shares of Glaukos (GKOS) tumbled 5.03% in pre-market trading on Thursday as multiple analysts adjusted their price targets for the company. The healthcare company, which specializes in novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, saw mixed reactions from Wall Street firms.
Mizuho lowered its price target on Glaukos to $130 from $150, while maintaining an Outperform rating. Truist Securities also cut its target price to $126 from $130. On the other hand, Wells Fargo raised its target price to $92 from $86, and JP Morgan increased its target to $110 from $100.
The divergent analyst views reflect uncertainties about Glaukos's future performance. While some firms remain optimistic about the company's long-term prospects, others are adjusting their expectations, possibly due to concerns about near-term challenges or valuation. Investors appear to be reacting cautiously to these mixed signals, leading to the significant pre-market decline in Glaukos's stock price.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.